Bill:
OK, I read the Eisinger article. Looks fairly balanced to me, even though it's very negative. However, it describes factors that drove the sector to this point. Yes, some companies will go out of business -- we've lost something like four in the last month. Goodbye. Nobody is going to miss a SHMN. Nobody.
Eisinger said "Things got bad because of countless unanticipated blow-ups". Unanticipated by whom? This is bull, but.... it is true that "expert" analysts have largely been rotten.
He said "And the strong performance and growth of big phamaceuticals means they need bigger acquisitions and bigger drugs to make a financial impact." True in spirit and in most of practice, irrational as hell. And there are plenty of "bigger drugs" among biotech pipes.
The contributors to this thread are obviously doing better than the so-called experts. Beware of people that paint the sector with a broad brush. If Saks is going to tell you to buy the big caps in biotech, what is he needed for? One can say "buy AMGN, BGEN, IMNX, GENZ and MEDI and goodbye Saks baby!"
Bunch of chicken sh*t dogma. I've been doing well in the lower tiers through the slaughter, and I'm going to do better in the coming months.
Hope everyone is having a great weekend!
Rick |
